JP2019519527A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519527A5
JP2019519527A5 JP2018561639A JP2018561639A JP2019519527A5 JP 2019519527 A5 JP2019519527 A5 JP 2019519527A5 JP 2018561639 A JP2018561639 A JP 2018561639A JP 2018561639 A JP2018561639 A JP 2018561639A JP 2019519527 A5 JP2019519527 A5 JP 2019519527A5
Authority
JP
Japan
Prior art keywords
domain monomer
domain
construct
polypeptide
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018561639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034087 external-priority patent/WO2017205436A1/en
Publication of JP2019519527A publication Critical patent/JP2019519527A/ja
Publication of JP2019519527A5 publication Critical patent/JP2019519527A5/ja
Priority to JP2022010912A priority Critical patent/JP2022068176A/ja
Priority to JP2024193057A priority patent/JP2025026880A/ja
Withdrawn legal-status Critical Current

Links

JP2018561639A 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法 Withdrawn JP2019519527A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010912A JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法
JP2024193057A JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたFcコンストラクトに関する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034087 WO2017205436A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010912A Division JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法

Publications (2)

Publication Number Publication Date
JP2019519527A JP2019519527A (ja) 2019-07-11
JP2019519527A5 true JP2019519527A5 (cg-RX-API-DMAC7.html) 2020-07-02

Family

ID=60412547

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018561641A Active JP7045333B6 (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法
JP2018561639A Withdrawn JP2019519527A (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたFcコンストラクトに関する組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018561641A Active JP7045333B6 (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたFcコンストラクトに関する組成物及び方法

Country Status (14)

Country Link
US (4) US11623964B2 (cg-RX-API-DMAC7.html)
EP (2) EP3464376A4 (cg-RX-API-DMAC7.html)
JP (5) JP7045333B6 (cg-RX-API-DMAC7.html)
KR (3) KR102590061B1 (cg-RX-API-DMAC7.html)
CN (4) CN116063540A (cg-RX-API-DMAC7.html)
AU (2) AU2017272111B2 (cg-RX-API-DMAC7.html)
BR (2) BR112018074032A2 (cg-RX-API-DMAC7.html)
CA (2) CA3025310A1 (cg-RX-API-DMAC7.html)
DK (1) DK3484514T3 (cg-RX-API-DMAC7.html)
ES (1) ES2973251T3 (cg-RX-API-DMAC7.html)
IL (3) IL309293A (cg-RX-API-DMAC7.html)
PL (1) PL3484514T3 (cg-RX-API-DMAC7.html)
SG (3) SG11201810465RA (cg-RX-API-DMAC7.html)
WO (2) WO2017205434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN113164591A (zh) * 2018-07-11 2021-07-23 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
WO2020014419A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
US20210317227A1 (en) * 2018-07-11 2021-10-14 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CA3106254A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021000288A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
WO2020014429A2 (en) * 2018-07-11 2020-01-16 Kurtagic Elma Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
KR20210044218A (ko) * 2018-07-11 2021-04-22 모멘타 파머슈티컬스 인코포레이티드 CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997047732A2 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
SI2185589T1 (sl) * 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
CA2762302A1 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
SG191233A1 (en) * 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. ヘテロ二量体免疫グロブリン
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2013270682A1 (en) * 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
MX2014015557A (es) 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
CA2888519C (en) * 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
CN113248613B (zh) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
CN106068274A (zh) 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
CN106132994A (zh) 2014-03-05 2016-11-16 Ucb生物制药私人有限公司 多聚体Fc蛋白
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Fcタンパク質
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
CN110650748B (zh) * 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Similar Documents

Publication Publication Date Title
JP7496091B2 (ja) 合理的に設計された新規なタンパク質組成物
Lu et al. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding
HRP20191334T1 (hr) Anti-fcrn antitijela
Monnet et al. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
Lim et al. Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis
Dekkers et al. Affinity of human IgG subclasses to mouse Fc gamma receptors
Stapleton et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
JP2022191486A (ja) ヒト抗il-33中和モノクローナル抗体
JP2012516158A5 (cg-RX-API-DMAC7.html)
Mester et al. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
JP2020501550A5 (cg-RX-API-DMAC7.html)
JP2017531427A5 (cg-RX-API-DMAC7.html)
HRP20192006T1 (hr) Antitijela specifična za fcrn
TWI797124B (zh) 抗干擾素-γ之抗體及其應用
JP2019519227A5 (cg-RX-API-DMAC7.html)
Zhang et al. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
JP2019515652A5 (cg-RX-API-DMAC7.html)
Taylor et al. Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure
CN104968675A (zh) 识别mhc ii类限制性mage-a3的t细胞受体
Haraya et al. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
CN117616050A (zh) 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
JP2024521405A5 (cg-RX-API-DMAC7.html)
CN108350069B (zh) 针对il-23的多肽
CN108473571A (zh) 结合人Fc受体的融合蛋白
JP2020532969A5 (cg-RX-API-DMAC7.html)